Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to learn more about the pathophysiology of acute coronary syndrome
(ACS) and to evaluate the mechanisms responsible of the action and benefits of ticagrelor.
Ticagrelor is an oral and reversible inhibitor of P2Y12 receptor. Few information is
available about the action of ticagrelor on the molecules involved in thrombogenesis and
platelets activation in ACS.
The aim of this study is to evaluate the mechanisms of ticagrelor action in vivo.
It was observed that patients with myocardial infarction have higher blood levels of
microparticles than patients with unstable angina or stable angina.
The investigators assumed that ticagrelor benefits are represented by a reduction of
microparticle levels, a marker of endothelial dysfunction in patients with cardiovascular
disease, and by a modification in microRNAs pattern, fragments of mRNA that have a regulatory
action in various cellular processes (such as proliferation, differentiation, growth and
cellular death) and represent new biomarkers in ACS.